





Predictive Significance of Sperm DNA Fragmentation Testing in Early Pregnancy Loss in Infertile Couples Undergoing Intracytoplasmic Sperm Injection

Minh Tam Le ^{1,2}

Trung Van Nguyen ¹

Thai Thanh Thi Nguyen ¹

Hiep Tuyet Thi Nguyen ¹

Duong Dinh Le ³

Vu Quoc Huy Nguyen ²

¹Center for Reproductive Endocrinology and Infertility, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam; ²Department of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam; ³Department of Public Health, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam

Objective: This study aimed to determine the role of sperm DNA fragmentation as a marker that could predict early pregnancy loss (EPL), either independently or in combination with another marker or markers, after intracytoplasmic sperm injection (ICSI) cycles.

Methods: This prospective descriptive cohort study retrieved data from 162 couples who underwent their first ICSI cycles at the Center for Reproductive Endocrinology and Infertility of Hue University Hospital in Vietnam from May 2018 to December 2019. General characteristics, semen parameters, sperm DNA fragmentation index (DFI), fertilization, embryo development, pregnancy rates, and EPL were assessed. The receiver-operating characteristic (ROC) method was performed to identify the threshold of DFI in EPL. Multivariate analysis was used to demonstrate the relationship between the sperm DNA fragmentation level and EPL.

Results: Of 162 ICSI cycles, 23 (14.2%) involved EPL. There was no significant difference between the sperm DNA fragmentation rate and the overall rate of pregnancy loss, although the negative pregnancy outcome group had a median DFI that was higher than that of the positive pregnancy outcome group (20% vs 17.8%). The ROC analysis indicated that a sperm DNA fragmentation rate of 16.6% was the priority cut-off that could be used to distinguish EPL with a sensitivity of 73.9% (95% confidence interval [CI], 67.15–80.67) and specificity of 47.48% (95% CI, 39.79–55.17). The multivariate analysis confirmed that in female factors such as age, body mass index (BMI), and sperm DNA fragmentation level affected the EPL rate. However, a combination of the sperm DNA fragmentation level and female age or female BMI could not sufficiently predict EPL.

Conclusion: EPL can be affected by multiple factors including sperm DNA fragmentation; however, there is no sufficient evidence indicating that sperm DNA fragmentation, both as a single marker and combined with other markers, is a good predictor of EPL.

Keywords: sperm DNA fragmentation, intracytoplasmic sperm injection, early pregnancy loss, infertility, assisted reproductive technology

Introduction

Infertility affects an estimated 15% of couples; of these couples, male factors account for 20% to 70% of infertility cases, and the percentage of male infertility ranges from 2.5% to 12%.¹ The sperm DNA fragmentation index (DFI) is clinically useful for assessing male fertility potential or as a prognostic test to determine if infertility treatment is necessary.^{2,3} In the field of assisted reproductive technology

Correspondence: Minh Tam Le
Center for Reproductive Endocrinology and Infertility, Hue University of Medicine and Pharmacy, Hue University, 06 Ngo Quyen Street, Hue City, Vietnam
Tel +84 989228779
Email leminhtam@huemed-univ.edu.vn

(ART) and andrology, sperm DNA fragmentation tests have been recommended to diagnose unexplained infertility, repeated implantation failure, and issues of the varicocele.⁴ Male factors, such as sperm DNA damage, can impact not only the fertilization process but also embryo gene expression and development.^{5–8} However, the impact of the DFI and embryo quality on pregnancy outcomes is controversial. Several publications have shown an association between high DFI and embryo quality regarding embryo formation⁹ and embryo quality scores.¹⁰ A higher DFI is correlated with poor embryo development and lower implantation rate during intracytoplasmic sperm injection (ICSI) cycles for couples with female factor infertility.¹¹ ICSI is recommended as a better choice than in vitro fertilization (IVF) for improving pregnancy outcomes of patients who have sperm with a high DFI.¹² Conversely, other studies concluded that the DFI was not correlated with blastocyst aneuploidy or morphological grading,¹³ total blastocyst number, or the number of blastocysts with good quality.¹⁴

Recent studies have reported an association between a high DFI and miscarriage after ICSI^{11,15,16} and between a high DFI and recurrent natural pregnancy loss.¹⁷ A meta-analysis of 8068 IVF/ICSI cycles reported by 41 articles suggested that sperm DNA damage negatively affected clinical pregnancy following IVF and/or ICSI treatment.¹⁸ However, other studies did not find a significant association between DFI and miscarriage¹² or between DFI and live birth rates¹⁹ of pregnancies associated with both IUI and ICSI cycles.²⁰

Furthermore, the DFI value that is a negative factor in pregnancy remains unclear. Different cut-off values for DFI have been presumed for distinguishing between men with normal and abnormal semen characteristics, with predictive values varying from 18%²¹ to 26.1%²² as follows: 19.9% according to a sperm chromatin structure assay (SCSA); 22.08% according to the terminal deoxynucleotidyl transferase UTP nick-end labeling (TUNEL) assay; 24.74% according to the sperm chromatin dispersion (SCD) test; and 48.47% according to the comet assay.^{23,24} Benchaib et al reported a four-fold increased risk of miscarriage when the DFI exceeded 15% for pregnancies associated with IVF/ICSI cycles.²⁵ A DFI threshold between 20% and 30% was used in some studies to evaluate the relationship between DFI and semen parameters, between DFI and embryo quality, as well as outcomes of pregnancies associated with assisted reproductive technology (ART).^{26–28} Some

studies have shown different DFI cut-off values when using the receiver-operating characteristic (ROC) curve to predict top-quality or grade A embryo formation rates (DFI using the SCD test, 30.7%),⁹ to predict the clinical pregnancy rate (DFI using the SCD test, 27.3%),²⁹ and to predict the miscarriage rate (DFI using the TUNEL test, 13%).¹⁵ As the impact of the DFI on ICSI outcomes as well as EPL after ICSI remains controversial, this study aimed to determine the role of sperm DNA fragmentation alone or in combination with other female factors in the prediction of EPL after ICSI.

Materials and Methods

This prospective descriptive cohort study included data of infertile couples who underwent ICSI from May 2018 to May 2019 at the Center for Reproductive Endocrinology and Infertility of Hue University Hospital in Vietnam. The inclusion criteria were couples with primary infertility undergoing their first ICSI cycle with frozen embryo transfer resulting in pregnancy outcomes and complete follow-up examinations until 12 weeks of gestational age. Exclusion criteria were men who were unable to ejaculate, men who had a general infection or urogenital infection, retrograde ejaculation, sperm from cryopreservation or surgical extraction, extremely low sperm counts (<1 million/mL), and azoospermia. IVF cycles with gamete donors and females with severe endometriosis (grade 3 and grade 4) were also excluded from the study.

The sample size was calculated for the rate estimate investigation as follows: $n \geq Z_{\alpha/2}^2 \frac{p(1-p)}{\Delta^2}$

This equation resulted in the following: $p = 0.06$,¹⁵ $\Delta = 0.05$, $\alpha = 0.05$, and $Z_{\alpha/2} = 1.96$ (95% confidence); to estimate prevalence of miscarriage for each IVF cycle, the minimum sample size was estimated to be at least 87 subjects. A total of 162 couples were recruited for the study population.

The study was approved by the ethics committee of Hue University of Medicine and Pharmacy (number H2019/432). Written informed consent was obtained from all patients.

Semen Analysis

Semen samples were collected from men after they masturbated in the laboratory at 3 to 5 days after abstinence. After liquefaction for 30 minutes, semen samples were evaluated for sperm motility, vitality, concentration, and morphology in accordance with the 2010 guidelines of the World Health Organization (WHO).

Sperm DNA Fragmentation

Sperm DNA fragmentation was measured using an SCD test (Halosperm kit[®]; Halotech, Madrid, Spain), which is a fast method based on controlled DNA denaturation and protein depletion to determine DNA fragmentation in sperm cells. A total of 500 sperms were examined by only one highly trained technician to decrease variability. DFI was expressed as the percentage of sperms with a small halo, the percentage without halo, and the percentage of degraded spermatozoa out of a total of 500 male gametes. The slides were observed by two highly trained technicians who calculated the average percentage of the two results to avoid bias.

Controlled Ovarian Hyperstimulation

Women who underwent IVF cycles were treated with controlled ovarian hyperstimulation using a GnRH antagonist protocol. Recombinant follicle-stimulating hormone (FSH; follitropin alfa) was administered with a starting dose of 225 IU (Gonal F[®]; Merck KGaA, Darmstadt, Germany) that was adjusted based on the number of developed follicles. Oocyte retrievals were performed 35 to 36 hours after administration of a trigger injection of human chorionic gonadotropin (hCG) 10,000 IU intramuscularly (Pregnyl[®]; Merck Sharp & Dohme Limited, Hertfordshire, UK) by ultrasound-guided follicle aspiration with a single-lumen needle (Vitrolife, Frölunda, Sweden).

Semen Preparation

Sperm samples were prepared using a two-layer density gradient centrifugation technique using 45% and 90% Sil-selects plus (Fertipro, Beernem, Belgium). Sperm samples were washed twice with 3 mL Spermrinse (Vitrolife) before being used for ICSI.

Intracytoplasmic Sperm Injection and Embryo Culture

Mature oocytes were determined after the oocyte cumulus complex (OCC) was denuded with HYASE 80 IU (Vitrolife) and pipetted with a 135- μ m inner diameter pipette. Insemination via ICSI was performed with a mature oocyte and prepared sperm 3 hours after retrieval. The injected oocyte was cultured in a single drop of 20 μ L of G-TL (Vitrolife) covered with 3 mL Ovoil (Vitrolife) under conditions of 6.0% CO₂ and 5.0% O₂. At 16 to 18 hours after the injection, fertilized oocytes were determined by the presence of two pronuclei. Embryos were

evaluated according to the Istanbul consensus on day 2. Top-grade embryos were defined as those with all of the following characteristics: four or more cells on day 2, less than 10% fragmentation, and no multinucleated cells.

Embryo Vitricification and Warming

Embryos with fragmentation less than 25% and embryos with more than two blastomeres on day 2 were selected for vitrification. Embryo vitrification was performed with a Cryotop device and commercially available medium (Kitazato, Tokyo, Japan); the protocol was in accordance with the instructions of the manufacturer. After open system vitrification, the embryos were stored in liquid nitrogen.

Artificial endometrial preparation was conducted by using estradiol 8 mg/day (2 mg \times 4 tablets; Progynova[®]; Bayer, Leverkusen, Germany) divided as 4 mg twice daily. Secretory transformation with progesterone (Crinone Gel[®] 8%; Merck KGaA, Darmstadt, Germany) was administered vaginally at a dose of 90 mg twice daily. Embryos used for transfer were determined when the endometrium had a thickness of 7 mm or more. Embryo warming was performed using a warming solution (Kitazato) according to the manufacturer's instructions. After warming, embryos were cultured in a group, applied with 20 μ L of G-TL (Vitrolife), covered with 3 mL of Ovoil (Vitrolife), and stored with overnight under conditions of 6.0% CO₂ and 5.0% O₂.

Embryo Transfer

Embryos were placed in 1 mL of Embryoglu (Vitrolife) for 15 to 30 minutes before being loaded into the catheter (Kitazato); then, they were transferred back to the uterus under transvaginal ultrasound guidance.

Clinical Follow-Up

Serum beta-hCG was measured 14 days after embryo transfer; a result of more than 50 mIU/mL was considered beta-hCG-positive. These women underwent a transvaginal ultrasound scan 2 weeks later. Clinical pregnancy was determined by the presence of a gestational sac and fetal cardiac activity, which were determined at 4 weeks after embryo transfer. The implantation rate was calculated based on the number of gestational sacs per embryo transferred. A biochemical pregnancy was defined as beta-hCG-positive cases without any gestational sac at 4 weeks after embryo transfer. Ongoing pregnancy was defined as fetal development at 12 weeks of gestational age. Moreover, EPL




Figure 1 Flowchart of ICSI cycle outcomes.

included biochemical pregnancy, anembryonic miscarriage, and embryonic miscarriage (miscarriage subgroups); this classification was based on the consensus statement of terminology of the European Society of Human Reproduction and Embryology.³⁰

Statistical Analysis

Descriptive statistics are demonstrated by the number and percentage for categorical data and by the mean and standard deviation or median with interquartile value (IQR) for continuous data. The chi-square test, Fisher's exact test, Student's *t*-test, and Mann–Whitney test were used to compare the appropriate categorical or continuous variables with ICSI outcomes. The ROC analysis was performed to identify the DFI value to predict ICSI outcomes using the area under curve (AUC) or selecting the optimal DFI threshold to predict EPL. A multivariate analysis adjusted for covariates was performed to demonstrate the association between the sperm DNA fragmentation level and EPL. All tested hypotheses considered $p=0.05$ as statistically significant.

Results

A total of 162 couples undergoing their first ICSI cycles were recruited. Pregnancy outcomes were followed-up until 12 weeks of gestation. ICSI outcomes are presented in Figure 1.

EPL included biochemical pregnancy loss, anembryonic pregnancy, and embryonic miscarriage. The beta-hCG-positive rate of the 162 ICSI cycles was 53.7% (87/162), the ongoing pregnancy rate was 39.5%, and the EPL rate was 14.2%.

Baseline characteristics of couples undergoing ICSI and pregnancy outcomes (positive pregnancy group and negative pregnancy group) are presented in Table 1. There was a significant association among pregnancy, infertility type, and anti-Müllerian hormone (AMH) level. The positive pregnancy rate was 57.6% and 22.2% for those with primary infertility and secondary infertility, respectively (significance, $p<0.01$). The median AMH level was significantly different between the positive and negative pregnancy outcome groups. Other factors such as infertility duration, male age, and semen parameters were not significantly different between these two groups.

Embryo quality and pregnancy outcomes according to the DFI are shown in Table 2. A statistically significant difference in the DFI was observed only for the clinical miscarriage subgroup (34.5 ± 22.8 vs 22.7 ± 17.2 ; $p=0.03$). Although not significantly different, the DFI value was higher for the subgroups with a low fertilization rate (27.4 ± 22.1 vs 22.05 ± 15.3), with a low number of usable embryos (29.9 ± 26.5 vs 22.8 ± 16.1), and with EPL (26.3 ± 19.2 vs 23.0 ± 17.2).

Table I Baseline Characteristics of Participants and Distribution in Subgroups of Pregnancy Outcomes

| Characteristics | Total (n=162) | Pregnancy (+) (n=87) | Pregnancy (-) (n=75) | p-value |
|------------------------------|---------------------|-------------------------|-------------------------|---------|
| Infertile couples | | | | |
| Infertility duration (years) | | | | |
| <3 | 21 (13.0) | 10 (47.6) | 11 (52.4) | 0.55 |
| ≥3 | 141 (87.0) | 77 (54.6) | 64 (45.4) | |
| Infertility type | | | | 0.005 |
| Primary | 144 (88.9) | 83 (57.6) | 61 (42.4) | |
| Secondary | 18 (11.1) | 4 (22.2) | 14 (77.8) | |
| Geography | | | | 0.86 |
| Urban | 83 (51.2) | 44 (53.0) | 39 (47.0) | |
| Rural | 79 (48.8) | 43 (54.4) | 36 (45.6) | |
| Husband | | | | |
| Age (years) | 36 (32–40) | 36 (32–39) | 37 (32–41) | 0.17 |
| Education | | | | 0.52 |
| School grade | 66 (40.7) | 33 (50.0) | 33 (50.0) | |
| College/University | 96 (59.3) | 54 (56.3) | 42 (43.7) | 0.1 |
| BMI (kg/m ²) | 23.67 (21.63–25.91) | 23.03 (21.30–25.53) | 24.22 (22.04–26.03) | |
| Waist (cm) | 84 (77–90) | 82 (76–89) | 85 (80–90) | 1.13 |
| WHR | 0.88 (0.84–0.91) | 0.88 (0.84–0.91) | 0.89 (0.85–0.91) | 0.21 |
| Semen parameters | | | | |
| Concentration | 32 (22–41) | 31 (22–41) | 32 (23–42) | 0.33 |
| Vitality | 79 (72–83) | 78 (71–83) | 80 (74–84) | 0.18 |
| Sperm PR motility (%) | 30 (21–39) | 28 (15–39) | 32 (23–39) | 0.08 |
| Morphology | 3 (2–5) | 3 (2–5) | 3 (2–5) | 0.23 |
| DFI | 18.1 (11.4–31) | 18.2 (11–31) | 17.8 (11.4–31.6) | 0.81 |
| Wife | | | | |
| Age (years) | 33 (30–36) | 32 (30–35) | 33 (30–37) | 0.05 |
| BMI (kg/m ²) | 20.57 (19.53–22.27) | 20.55 (19.53–22.22) | 20.70 (19.53–22.60) | 0.76 |
| AMH (ng/mL) | 2.78 (1.48–4.54) | 3.33 (2.1–5.7) | 2.16 (0.93–3.55) | 0.0003 |
| Miscarriage history | | | | 0.46 |
| Yes | 37 (22.8) | 22 (59.5) | 15 (40.5) | |
| No | 125 (77.2) | 65 (52.0) | 60 (48.0) | |

Notes: All continuous variables were presented as mean ± standard deviation (mean ± SD) and were compared between two outcomes groups. The categorical variables were illustrated by the observational number and percentages.

Abbreviations: AMH, anti-Mullerian hormone; BMI, body mass index; DFI, DNA fragmentation index; FSH, follicle-stimulating hormone; PR, progressive; WHR, waist-hip ratio.

The ROC curve analyses showed that varying percentages of sperm DNA fragmentation were used to calculate the optimum sensitivity and specificity of ICSI outcomes (Table 3). The recommended AUC was 0.56 (95% confidence interval [CI], 0.48–0.64) for an EPL rate of 16.6% with sperm DNA fragmentation.

Regarding sperm quality and embryo quality related to the DFI threshold, there were statistically significant differences in the median (IQR) male BMI, waist circumference, and waist-to-hip ratio (WHR) of groups with DFI less than 16.6% and DFI more than 16.6% ($p=0.04$, $p=0.02$, and $p=0.003$, respectively) (Table 4).

Table 2 DNA Fragmentation Index Results in Embryo Quality and Pregnancy Outcomes

| Outcomes | DFI | | | | | |
|-----------------------|-----|------|------------------|----------|------------------|------|
| | n | % | Mean \pm SD | Min-Max | Median (IQR) | p |
| Fertilization rate | | | | | | |
| < 75% | 43 | 26.5 | 27.4 \pm 22.1 | 4.4–81.6 | 19.4 (11–38.2) | 0.42 |
| \geq 75% | 119 | 73.5 | 22.05 \pm 15.3 | 4.2–88.4 | 17.8 (11.4–29) | |
| Usable embryos | | | | | | |
| <50% | 16 | 9.9 | 29.9 \pm 26.5 | 6.2–81.6 | 18.4 (12.9–41.3) | 0.61 |
| \geq 50% | 146 | 90.1 | 22.8 \pm 16.1 | 4.2–88.4 | 18.1 (11–31) | |
| hCG test | | | | | | |
| hCG (+) | 87 | 53.7 | 23.6 \pm 17.1 | 4.4–81.6 | 18.2 (11–31) | 0.81 |
| hCG (-) | 75 | 46.3 | 23.3 \pm 17.9 | 4.2–88.4 | 17.8 (11.4–31.6) | |
| Biochemical pregnancy | | | | | | |
| Yes | 12 | 7.4 | 23.6 \pm 17.1 | 4.4–81.6 | 11 (31–97) | 0.42 |
| No | 150 | 92.6 | 23.3 \pm 17.9 | 4.2–88.4 | 11.4 (31.6–75) | |
| Clinical pregnancy | | | | | | |
| Yes | 75 | 46.3 | 24.4 \pm 17.8 | 4.4–81.6 | 18.4 (12–32) | 0.51 |
| No | 87 | 53.7 | 22.7 \pm 17.2 | 4.2–88.4 | 17.8 (10.4–29.4) | |
| Miscarriage | | | | | | |
| Yes | 11 | 6.8 | 34.5 \pm 22.8 | 13.4–77 | 24.8 (17.4–63.8) | 0.03 |
| No | 151 | 93.2 | 22.7 \pm 16.8 | 4.2–88.4 | 17.8 (11–30.6) | |
| Pregnancy loss | | | | | | |
| Yes | 23 | 14.2 | 26.3 \pm 19.2 | 5.6–77 | 20 (13.4–31.8) | 0.35 |
| No | 139 | 85.8 | 23.0 \pm 17.2 | 4.2–88.4 | 17.8 (11–31) | |
| Total | 162 | | 23.5 \pm 17.4 | 4.2–88.4 | 18.1 (11.4–31) | |

Abbreviations: DFI, DNA fragmentation index; hCG, human chorionic gonadotropin.

Table 3 The Predicted Values of ICSI Outcomes by Sperm DNA Fragmentation

| Outcomes | Yes | Threshold | AUC | 95% CI of AUC | Se | Sp | PPV | NPV |
|--------------------|-----|-----------|------|---------------|------|------|------|------|
| Beta-hCG positive | 87 | 22.2 | 0.51 | 0.42–0.60 | 43.7 | 65.3 | 59.4 | 50.0 |
| Clinical pregnancy | 75 | 23.6 | 0.53 | 0.45–0.61 | 42.7 | 71.3 | 56.1 | 59.0 |
| Ongoing pregnancy | 64 | 20.8 | 0.48 | 0.40–0.56 | 45.3 | 59.2 | 42.0 | 62.4 |
| Pregnancy loss | 23 | 16.6 | 0.56 | 0.48–0.64 | 73.9 | 47.5 | 18.9 | 91.7 |

Abbreviations: hCG, human chorionic gonadotropin; AUC, area under curve; Se, sensitivity; Sp, specificity; PPV, positive predictive values; NPV, negative predictive values.

A multivariate analysis of the relationship between the DFI and EPL (Table 5) indicated that EPL was more likely to occur in older women (age, 35 years or older; odds ratio [OR], 5.87; 95% CI, 1.72–20.09; $p=0.005$), women with an abnormal BMI (OR, 3.20; 95% CI, 1.10–9.28; $p=0.032$), and women with DFI ≥ 16 (OR, 3.2; 95% CI, 1.10–9.28; $p=0.032$).

Table 6 presents the values of the DFI level, female age, and female BMI as predictors (single factor or combined

factors) of EPL. The optimal cut-off point for DFI to predict EPL was defined as 16.6%, with a sensitivity of 73.9%, specificity of 47.5%, positive predictive value (PPV) of 18.9%, and negative predictive value (NPV) of 91.7%. Despite a significant association among female age, female BMI, and EPL (Table 5), these were not significant predictors of EPL when the DFI level was adjusted for female age or female BMI. The combination of the DFI and female age can predict EPL with a sensitivity of 43.5%, specificity of

Table 4 Related Factors and Embryo Quality by DNA Fragmentation Index Threshold

| Factors | DFI \geq 16.6 | DFI < 16.6 | p-value |
|--------------------------|-------------------|-------------------|---------|
| Husband | | | |
| Age (years) | 36.5 (32–41) | 36 (32–39) | 0.91 |
| BMI (kg/m ²) | 24.28 (22.2–26.3) | 23.03 (21.3–24.9) | 0.04 |
| Waist (cm) | 85 (79–91) | 80.5 (75–88.5) | 0.02 |
| WHR | 0.897 (0.85–0.9) | 0.861 (0.83–0.89) | 0.003 |
| Sperm quality | | | |
| Concentration (mil/mL) | 30 (22–40) | 32.5 (22.5–43) | 0.09 |
| Vitality (%) | 80 (71–83) | 79 (73.5–83) | 0.74 |
| Progressive motility (%) | 30 (20–40) | 31 (22.5–38) | 0.59 |
| Normal morphology (%) | 3 (2–5) | 3 (2–5.5) | 0.33 |
| Embryo quality | | | |
| Blastomeres \geq 4 | 79.58 (67.5–100) | 80 (66.7–97.2) | 0.99 |
| Fragmentation <10% | 90.45 (69.6–100) | 85.67 (60–100) | 0.36 |
| Grade A embryo | 66.67 (50–81.5) | 60 (41.4–86.0) | 0.49 |
| Usable embryos (%) | 100 (90.5–100) | 100 (83.3–100) | 0.33 |
| Embryos transferred* | 2 (2–3) | 2 (2–3) | 0.51 |

Notes: *Number of transferred embryos was presented by the median and interquartile range.

Abbreviations: BMI, body mass index; DFI, DNA fragmentation index; hCG, human chorionic gonadotropin; WHR, waist-hip ratio.

Table 5 Predictors of Early Pregnancy Loss in Multivariate Analysis

| Predictors | OR Adjusted* | 95% CI | p |
|-------------------------------|--------------|------------|-------|
| Husband's age | 0.90 | 0.808–1.01 | 0.071 |
| Wife's age | | | |
| <35 | 1 (ref) | | |
| \geq 35 | 5.87 | 1.72–20.09 | 0.005 |
| Wife's BMI | | | |
| Normal (18.5–<23) | 1 (ref) | | |
| Abnormal (<18.5 or \geq 23) | 4.18 | 1.58–11.02 | 0.004 |
| DFI | | | |
| <16.6 | 1 (ref) | | |
| \geq 16.6 | 3.20 | 1.10–9.28 | 0.032 |

Notes: *By adjustment with age of the infertile couples (male and female) in the generalized linear models.

Abbreviations: BMI, body mass index; DFI, DNA fragmentation index; OR, odd ratio.

89.9%, PPV of 36.4%, and a NPV of 89.9%. Similarly, the combination of DFI and female BMI resulted values of 39.1%, 87.8%, 34.6%, and 89.7% respectively.

Discussion

The influence of sperm DNA damage on embryo quality during ICSI cycles is a controversial issue. With the ICSI method, sperm is selected based on motility and morphology, active insemination in the oocyte cytoplasm, and the ability to overcome several barriers of natural selection;³¹ however, despite this selection, sperm may have

contained damaged DNA.¹⁰ Recent studies have shown indirect effects of sperm DNA damage on fertilization and early embryonic development through the process of genetic material repair that occurred in the oocyte. Logically, embryo development could be delayed; poor embryo quality was found in the group with high DFI.^{9,32} The ICSI results of patients with DFI \geq 30% indicated a statistically significant decrease in fertilization rate, normal cleavage speed rate, and top-grade embryo rate on day 3 compared to those with DFI <30%.¹¹ In the present study, a cut-off value of DFI \geq 16.6% based on

Table 6 The Values of Exploratory Factors in Prognosis of Early Pregnancy Loss by Independent or in Combined Predictors

| Predictors | Pregnancy Loss | | Sensitivity (95% CI) | Specificity (95% CI) | PPV | NPV |
|------------------------------|----------------|-----|----------------------|----------------------|------------------|------------------|
| | Yes | No | | | | |
| Age | | | | | | |
| ≥35 | 14 | 48 | 60.9 (53.4–68.4) | 65.5 (58.2–72.8) | 22.9 (16.1–29.0) | 91.0 (86.6–95.4) |
| <35 | 9 | 91 | | | | |
| BMI | | | | | | |
| Abnormal | 13 | 34 | 56.5 (48.5–64.2) | 75.5 (68.9–82.2) | 27.7 (20.8–34.6) | 91.3 (87.0–95.6) |
| Normal | 10 | 105 | | | | |
| DFI | | | | | | |
| ≥16.6 | 17 | 73 | 73.9 (67.2–80.7) | 47.5 (39.8–55.2) | 18.9 (12.9–24.9) | 91.7 (87.4–95.9) |
| <16.6 | 6 | 66 | | | | |
| Age - BMI | | | | | | |
| ≥ 35 and BMI = abnormal | 8 | 14 | 34.8 (27.5–42.1) | 89.9 (85.3–94.6) | 36.4 (29.0–43.8) | 89.3 (84.5–94.1) |
| < 35 BMI = normal | 15 | 125 | | | | |
| DFI & Age | | | | | | |
| ≥16.6 and Age ≥35 | 10 | 23 | 43.5 (35.8–51.1) | 83.5 (77.7–89.2) | 30.3 (23.2–37.4) | 89.9 (85.3–94.6) |
| DFI <16.6 Age <35 | 13 | 116 | | | | |
| DFI & BMI | | | | | | |
| DFI ≥16.6 and BMI = abnormal | 9 | 17 | 39.1 (31.6–46.7) | 87.8 (82.7–92.8) | 34.6 (27.3–41.9) | 89.7 (85.0–94.4) |
| DFI <16.6 BMI = normal | 14 | 122 | | | | |

Abbreviations: BMI, body mass index and age of wife; DFI, DNA fragmentation index; PPV, Positive predictive values; NPV, negative predictive values.

the ROC method to predict an increased risk of EPL when analyzing embryogenesis using this threshold, showed no significant differences in the fertilization rate, normal cleavage speed, and top-grade embryo rate on day 2. It should be explained that an increased DFI is insufficient to influence the fertilization process and early embryonic development. In fact, it was reported that the use of spermatozoa with damaged DNA did not affect the results of fertilization and early embryonic development until blastocyst formation.^{33,34}

The integrity of sperm DNA has an important role in fertilization and maintaining a normal pregnancy.³⁵ Especially, sperm DNA damage was supposed to be responsible for increasing early miscarriage risk. It was thought that the lack of proper chromatin structure in sperm due to fragmented DNA may inhibited gene expression and caused EPL.^{6,16} An association between sperm fragmentation DNA and IVF/ICSI failure by meta-analyses studies showed that increased DFI raised miscarriage rate.^{5,7,37} A previous meta-analysis showed a significant increase in miscarriage for patients with high DFI; this risk increased 2.16-times³⁶ to 2.48-times³⁷ for IVF and ICSI. In our study, there were statistically

significant differences in the DFI of the miscarriage subgroups; the sperm DFI with a cut-off of 16.6% increased the EPL rate 3.2 times ($p=0.032$). It is possible that unrepaired damage of sperm DNA may negatively affect the blastocyst development rate and result in a higher risk of EPL.

Although it has been reported that an increased DFI affects the incidence of EPL after ICSI, there is no homogenous DFI cut-off value. Violeta et al reported that DFI >27% was associated with an increased risk of EPL after ICSI (OR, 5.65; 95% CI, 4.32–7.11; $p<0.05$), including biochemical pregnancies and miscarriages.³⁸ Lopez et al used the ROC curve to calculate a DFI threshold value of 25.5% to predict successful and unsuccessful IVF/ICSI treatments; therefore, a value more than 25.5% could be associated with a higher probability of failed IVF.³⁹ The latest study by Borges et al involved the use of an SCD assay indicated a DFI cut-off of 30% resulted in a 2.5-fold miscarriage rate (DFI ≥30%: 42.8% miscarriage rate; DFI <30%: 16.8% miscarriage rate).¹¹ However, the ROC analysis also revealed a low cut-off value (DFI >13%) for predicting miscarriage.¹⁵

Several methodologies have been used to assess sperm DNA fragmentation and calculate DFI, such as the

TUNEL assay, comet assay, SCSA, and SCD test. Each method had advantages and disadvantages when used to evaluate sperm DNA fragmentation. The TUNEL assay and SCSA are two standardized sperm DNA fragmentation assessment methods with high repeatability. However, the disadvantages of these two methods is that the test requires expensive equipment and a high concentration of sperm. The comet assay provides visual images of double-strand DNA appearing at the head of the comet and damaged double-strand and single-strand DNA fragments forming the tail part. However, the protocols of the comet assay have not been standardized, and it is difficult to distinguish between endogenous DNA breaks and induced DNA breaks in the alkaline comet assay. The SCD assay is simple, quick, and has high reproducibility; it only requires a microscope, but the results of the SCD assay are greatly dependent on the skills of the person performs the test.³¹ Besides, although SCD tests measured fragmentation indirectly that was less sensitive than others, it might reflect later outcomes such as birth delivery and abortion rates.^{14,42} Primarily, because of the advantages of the SCD assay, we used it along with the equipment available in our laboratory to assess sperm DNA fragmentation levels during this study. Moreover, previous studies have shown that SCD can help predict the prognosis for male infertility and provide results similar to those of other methods when assessing sperm DNA fragmentation levels.²⁴

Female age-related declines in fertility have a greater impact than BMI on the cumulative live birth rate.⁴⁰ Jin et al reported that when DFI was >27.3%, the risk of EPL increased significantly for those with reduced and normal ovarian reserves. This suggested that sperm DNA fragmentation testing was particularly useful for couples when the female had a reduced ovarian reserve and high DFI.²⁹ Similarly, the study by Liang et al revealed that when female age was older than 30 years, women with DFI >30% had lower clinical pregnancy rates and fewer good-quality embryos than women with DFI ≤30%.⁴¹ In our study, the multivariate analysis indicated that female age and female abnormal BMI increased the risk of EPL in IVF cycles by 5.87 times ($p=0.005$) and 4.18 times ($p=0.004$), respectively.

Regarding the prediction of EPL, the DFI alone had high sensitivity (73.9%) and high NPV (91.7%) but low specificity (47.5%) and low PPV (18.9%). This means that the DFI value is not a good independent predictor of EPL after embryo transfer. The combination of DFI and other

female factors, including age or BMI, did not strongly improve the ability to predict EPL. Increased DFI and female age had higher specificity (83.5%) and NPV (89.9%), but sensitivity and PPV were very low. Similarly, the combination of DFI and female BMI had low sensitivity and low PPV. Lin et al also reported that when the DFI threshold was higher than 27%, the specificity was 85% specificity and the NPV was 96% for predicting miscarriage, but the sensitivity and PPV were very low; in the ICSI group, this DFI threshold for predicting miscarriage had 50% sensitivity, 78% specificity, and 94% NPV, but the PPV was very low.⁴²

The strength of the present study confirmed the effects of an increased DFI on the incidence of EPL after ICSI. Moreover, the data of our SCD test recommended a DFI threshold as low as 16.6% to predictive EPL. This study was limited because the choice of test as Halo is less sensitive than other sperm DNA fragmentation tests and this assessment may be a reason for the lack of association. Besides, follow-up to determine the birth rate rather than the ongoing pregnancy rate can provide a better understanding. Moreover, future studies with long-term follow-up may provide further insight into the relationship between DFI and the live birth rate.

In conclusion, the DFI is related to EPL after ICSI. Although it has high sensitivity and high NPV, the DFI should not be used as an independent predictor of EPL because of its low specificity. When DFI is combined with female factors such as age and BMI, its specificity for predicting EPL is improved but its sensitivity is not. This study determined that EPL can be affected by multiple factors, including sperm DNA fragmentation. However, there is insufficient evidence to support sperm DNA fragmentation as a good predictor of EPL.

Abbreviations

AMH, anti-mullerian hormone; AUC, area under curves; ARTs, assisted reproductive techniques; BMI, body mass index; CI, confidence interval; DNA, deoxyribonucleic acid; DFI, DNA fragmentation index; hCG, human chorionic gonadotropin; ICSI, intracytoplasmic sperm injection; SCD, sperm chromatin dispersion; SDF, sperm DNA fragmentation; SCSA, sperm chromatin structure assay; TUNEL, terminal deoxynucleotidyl transferase UTP nick-end labelling; PPV, positive predictive value; NPV, negative predictive value; Median (IQR), median and interquartile range.

Data Sharing Statement

All data are available and would be shown as requested.

Ethics Approval

This study was approved by the Ethics Committee of Hue University of Medicine and Pharmacy, numbered H2019/432. All information and data were encrypted and confidential. This study was conducted in accordance with the Declaration of Helsinki.

Consent for Publication

All authors have been involved in the research work and consent for publication.

Acknowledgments

The authors thank the staff of Hue Center of Reproductive Endocrinology and Infertility for support on data recruitment and we would like to express my gratitude to the peer reviewers and editors for their opinions and suggestions.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This work was supported by a research grant from Vietnam Ministry of Education and Training (grant number DHH2018-04-78). The grantor had no influence in the content of the publication.

Disclosure

The authors have no competing financial or other interests to declare in relation to this manuscript.

References

- Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. *Reprod Biol Endocrinol*. 2015;13:37. doi:10.1186/s12958-015-0032-1
- Panner Selvam MK, Agarwal A. A systematic review on sperm DNA fragmentation in male factor infertility: laboratory assessment. *Arab J Urol*. 2018;16(1):65–76. doi:10.1016/j.aju.2017.12.001
- Esteves SC, Santi D, Simoni M. An update on clinical and surgical interventions to reduce sperm DNA fragmentation in infertile men. *Andrology*. 2020;8(1):53–81. doi:10.1111/andr.12724
- Basar MM, Kahraman S. Clinical utility of sperm DNA fragmentation testing: practice recommendations based on clinical scenarios. *Transl Androl Urol*. 2017;6(Suppl 4):S574–S6. doi:10.21037/tau.2017.04.40
- Cho CL, Agarwal A. Role of sperm DNA fragmentation in male factor infertility: a systematic review. *Arab J Urol*. 2018;16(1):21–34. doi:10.1016/j.aju.2017.11.002
- McQueen DB, Zhang J, Robins JC. Sperm DNA fragmentation and recurrent pregnancy loss: a systematic review and meta-analysis. *Fertil Steril*. 2019;112(1):54–60.e3. doi:10.1016/j.fertnstert.2019.03.003
- Tan J, Taskin O, Albert A, Bedaiwy MA. Association between sperm DNA fragmentation and idiopathic recurrent pregnancy loss: a systematic review and meta-analysis. *Reprod Biomed Online*. 2019;38(6):951–960. doi:10.1016/j.rbmo.2018.12.029
- Le MT, Nguyen TAT, Nguyen HTT, et al. Does sperm DNA fragmentation correlate with semen parameters? *Reprod Med Biol*. 2019;18(4):390–396. doi:10.1002/rmb2.12297
- Kim SM, Kim SK, Jee BC, Kim SH. Effect of sperm DNA fragmentation on embryo quality in normal responder women in in vitro fertilization and intracytoplasmic sperm injection. *Yonsei Med J*. 2019;60(5):461–466. doi:10.3349/ymj.2019.60.5.461
- Salehi M, Afarinesh MR, Haghpanah T, Ghaffari Novin M, Farifteh F. Impact of sperm DNA fragmentation on ICSI outcome and incidence of apoptosis of human pre-implantation embryos obtained from in vitro matured MII oocytes. *Biochem Biophys Res Commun*. 2019;510(1):110–115. doi:10.1016/j.bbrc.2019.01.056
- Borges E, Zanetti BF, Setti AS, Braga D, Provenza RR, Iaconelli A. Sperm DNA fragmentation is correlated with poor embryo development, lower implantation rate, and higher miscarriage rate in reproductive cycles of non-male factor infertility. *Fertil Steril*. 2019;112(3):483–490. doi:10.1016/j.fertnstert.2019.04.029
- Chi HJ, Kim SG, Kim YY, et al. ICSI significantly improved the pregnancy rate of patients with a high sperm DNA fragmentation index. *Clin Exp Reprod Med*. 2017;44(3):132–140. doi:10.5653/cerm.2017.44.3.132
- Gat I, Tang K, Quach K, et al. Sperm DNA fragmentation index does not correlate with blastocyst aneuploidy or morphological grading. *PLoS One*. 2017;12(6):e0179002. doi:10.1371/journal.pone.0179002
- Antonouli S, Papatheodorou A, Panagiotidis Y, et al. The impact of sperm DNA fragmentation on ICSI outcome in cases of donated oocytes. *Arch Gynecol Obstet*. 2019;300(1):207–215. doi:10.1007/s00404-019-05133-9
- Choi HY, Kim SK, Kim SH, Choi YM, Jee BC. Impact of sperm DNA fragmentation on clinical in vitro fertilization outcomes. *Clin Exp Reprod Med*. 2017;44(4):224–231. doi:10.5653/cerm.2017.44.4.224
- Jerre E, Bungum M, Evenson D, Giwercman A. Sperm chromatin structure assay high DNA stainability sperm as a marker of early miscarriage after intracytoplasmic sperm injection. *Fertil Steril*. 2019;112(1):46–53 e2. doi:10.1016/j.fertnstert.2019.03.013
- Majzoub A, Agarwal A, Cho CL, Esteves SC. Sperm DNA fragmentation testing: a cross sectional survey on current practices of fertility specialists. *Transl Androl Urol*. 2017;6(Suppl 4):S710–s9. doi:10.21037/tau.2017.06.21
- Simon L, Zini A, Dyachenko A, Ciampi A, Carrell DT. A systematic review and meta-analysis to determine the effect of sperm DNA damage on in vitro fertilization and intracytoplasmic sperm injection outcome. *Asian J Androl*. 2017;19(1):80–90. doi:10.4103/1008-682X.182822
- Hachemi M, Bensaada M, Rouabah A, et al. Effect of spermatid nuclear quality on live birth rates in intracytoplasmic sperm injection. *J Hum Reprod Sci*. 2019;12(2):122–129. doi:10.4103/jhrs.JHRS_81_18

20. Siddhartha N, Reddy NS, Pandurangi M, Muthusamy T, Vembu R, Kasinathan K. The effect of sperm DNA fragmentation index on the outcome of intrauterine insemination and intracytoplasmic sperm injection. *J Hum Reprod Sci.* **2019**;12(3):189–198. doi:10.4103/jhrs.JHRS_22_19
21. Gill K, Jakubik J, Rosiak-Gill A, et al. Utility and predictive value of human standard semen parameters and sperm DNA dispersion for fertility potential. *Int J Environ Res Public Health.* **2019**;16(11):2004. doi:10.3390/ijerph16112004
22. Wiweko B, Utami P. Predictive value of sperm deoxyribonucleic acid (DNA) fragmentation index in male infertility. *Basic Clin Androl.* **2017**;27:1. doi:10.1186/s12610-016-0046-3
23. Javed A, Talkad MS, Ramaiah MK. Evaluation of sperm DNA fragmentation using multiple methods: a comparison of their predictive power for male infertility. *Clin Exp Reprod Med.* **2019**;46(1):14–21. doi:10.5653/cerm.2019.46.1.14
24. Ribas-Maynou J, Garcia-Peiro A, Fernandez-Encinas A, et al. Comprehensive analysis of sperm DNA fragmentation by five different assays: TUNEL assay, SCSA, SCD test and alkaline and neutral Comet assay. *Andrology.* **2013**;1(5):715–722. doi:10.1111/j.2047-2927.2013.00111.x
25. Benchaib M, Lornage J, Mazoyer C, Lejeune H, Salle B, Francois Guerin J. Sperm deoxyribonucleic acid fragmentation as a prognostic indicator of assisted reproductive technology outcome. *Fertil Steril.* **2007**;87(1):93–100. doi:10.1016/j.fertnstert.2006.05.057
26. Agarwal A, Majzoub A, Esteves SC, Ko E, Ramasamy R, Zini A. Clinical utility of sperm DNA fragmentation testing: practice recommendations based on clinical scenarios. *Transl Androl Urol.* **2016**;5(6):935. doi:10.21037/tau.2016.10.03
27. Nallepalli S, Nagireddy S, Vembu R, Pandurangi M, Daniel M. Estimation of sperm DNA fragmentation index in ICSI cycles: does it affect the outcome? *Fertil Steril.* **2018**;110(4):e291. doi:10.1016/j.fertnstert.2018.07.821
28. Sun T-C, Zhang Y, Li H-T, et al. Sperm DNA fragmentation index, as measured by sperm chromatin dispersion, might not predict assisted reproductive outcome. *Taiwan J Obstet Gynecol.* **2018**;57(4):493–498. doi:10.1016/j.tjog.2018.06.003
29. Jin J, Pan C, Fei Q, et al. Effect of sperm DNA fragmentation on the clinical outcomes for in vitro fertilization and intracytoplasmic sperm injection in women with different ovarian reserves. *Fertil Steril.* **2015**;103(4):910–916. doi:10.1016/j.fertnstert.2015.01.014
30. Kolte A, Bernardi L, Christiansen O, et al. Terminology for pregnancy loss prior to viability: a consensus statement from the ESHRE early pregnancy special interest group. *Human Reprod.* **2014**;30:495–498. doi:10.1093/humrep/deu299
31. Kim GY. What should be done for men with sperm DNA fragmentation? *Clin Exp Reprod Med.* **2018**;45(3):101–109. doi:10.5653/cerm.2018.45.3.101
32. Esbert M, Pacheco A, Soares SR, et al. High sperm DNA fragmentation delays human embryo kinetics when oocytes from young and healthy donors are microinjected. *Andrology.* **2018**;6(5):697–706. doi:10.1111/andr.12551
33. Tello-Mora P, Hernández-Cadena L, Pedraza J, López-Bayghen E, Quintanilla-Vega B. Acrosome reaction and chromatin integrity as additional parameters of semen analysis to predict fertilization and blastocyst rates. *Reprod Biol Endocrinol.* **2018**;16(1):102. doi:10.1186/s12958-018-0408-0
34. Bach PV, Schlegel PN. Sperm DNA damage and its role in IVF and ICSI. *Basic Clin Androl.* **2016**;26:15. doi:10.1186/s12610-016-0043-6
35. Sakkas D, Alvarez JG. Sperm DNA fragmentation: mechanisms of origin, impact on reproductive outcome, and analysis. *Fertil Steril.* **2010**;93(4):1027–1036. doi:10.1016/j.fertnstert.2009.10.046
36. Robinson L, Gallos ID, Conner SJ, et al. The effect of sperm DNA fragmentation on miscarriage rates: a systematic review and meta-analysis. *Human Reprod.* **2012**;27(10):2908–2917. doi:10.1093/humrep/des261
37. Zini A, Boman J, Belzile E, Ciampi A. Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: systematic review and meta-analysis editorial comment. *Human Reprod.* **2008**;23:2663–2668. doi:10.1093/humrep/den321
38. Violeta SR, Nina PA, Lyubomira OI, Svetlana PI, Emiliana IK. Sperm DNA integrity test and assisted reproductive technology (art) outcome. *J Biomed Clin Res.* **2016**;9(1):21–29. doi:10.1515/jbcr-2016-0003
39. Lopez G, Lafuente R, Checa MA, Carreras R, Brassesco M. Diagnostic value of sperm DNA fragmentation and sperm high-magnification for predicting outcome of assisted reproduction treatment. *Asian J Androl.* **2013**;15(6):790–794. doi:10.1038/aja.2013.81
40. Goldman RH, Farland LV, Thomas AM, Zera CA, Ginsburg ES. The combined impact of maternal age and body mass index on cumulative live birth following in vitro fertilization. *Am J Obstet Gynecol.* **2019**;221(6):617.e1–e13. doi:10.1016/j.ajog.2019.05.043
41. Liang X, Mao Y, Wang Y, Liu S, Yan J. Female age affects the utility of sperm DNA fragmentation in predicting IVF and ICSI outcomes. *Reprod Biomed Online.* **2019**;39(6):955–962. doi:10.1016/j.rbmo.2019.09.013
42. Lin M-H, Kuo-Kuang Lee R, Li S-H, Lu C-H, Sun F-J, Hwu Y-M. Sperm chromatin structure assay parameters are not related to fertilization rates, embryo quality, and pregnancy rates in in vitro fertilization and intracytoplasmic sperm injection, but might be related to spontaneous abortion rates. *Fertil Steril.* **2008**;90(2):352–359. doi:10.1016/j.fertnstert.2007.06.018

Research and Reports in Urology

Publish your work in this journal

Research and Reports in Urology is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease; Investigation and

treatment of urological disease; Pharmacology of drugs used for the treatment of urological disease. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/research-and-reports-in-urology-journal>

Dovepress